Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2021–2025

CONSENSE · A game change in continuous biosensing: Molecularly engineered affinity-based nanoswitches for personal monitoring

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2021-03-01 → 2025-08-31
Финансиране от ЕС
4 029 294 €
Участници
11
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Нанопревключватели, които променят формата си при свързване с определени биомаркери, се разработват за непрекъснат оптичен мониторинг на здравето. Това позволява получаване на данни в реално време, вместо чакането на лабораторни резултати, което помага за по-добро проследяване на болестите и ефекта от лечението.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

A game change in continuous biosensing: Molecularly engineered affinity-based nanoswitches for personal monitoring

Healthcare is in demand of real-time sensing technologies to continuously guard the state of patients based on real-time, precise, and reliable data. Fluctuations in biomolecular levels are conventionally determined through laboratory assays that analyze samples collected at multiple time points. However, these laboratory-based methodologies have long turnaround times, typically a day or more, making it impossible to develop measurement-and-control strategies with frequent measurements and rapid feedback. Therefore, novel generic biosensor technologies are needed for the continuous monitoring of biomarkers for the monitoring of disease status and treatment effects. The overarching aim of CONSENSE is to develop affinity-based biosensing technologies for the continuous monitoring of biomarkers by combining advanced engineering of biomolecular nanoswitches and optical detection by training 15 Early-Stage Researchers (ESRs) in the necessary scientific and transferable skills. The specific scientific objectives are: • Construct nanoscale biomolecular architectures that undergo conformational changes upon binding of a target molecule (WP1). • Develop optical read-out platforms that allow continuous optical monitoring of target molecules by detecting analyte-induced conformational switching (WP2). • System integration and preclinical validation (WP3).

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Generic technology that allows continuous sensing of a wide range of biomolecular parameters could revolutionise patient monitoring and enable truly personalised therapy. Commercial sensors are available for continuous monitoring of glucose, but do not exist for other molecules that are important for monitoring disease status and treatment effect, including peptides, proteins, hormones, and drugs. The ambition of CONSENSE is to provide a game change in continuous biomolecular sensing by combining advanced molecular engineering with tailored optical detection technologies to yield generic, affinity-based biosensing technologies. CONSENSE will focus on the construction of biomolecular nanoswitches that translate molecular binding into robust and well-defined conformational changes at length scales that can be detected by selected optical detection methods, providing unique possibilities to distinguish between specific and nonspecific binding. While the applications for this new technology are wide and varied, within CONSENSE we will focus on immune monitoring in critical care settings, where patients have an urgent need for continuous monitoring related to inflammation and immunotherapy. CONSENSE brings together internationally leading pioneers in biomolecular switch engineering with research groups that have an excellent track record in biosensor development using advanced optical approaches, including two high-tech companies that have spun out from these groups. The consortium is completed by a strong network of partner industries and organisations, including four large medical technology companies, clinical experts, and seven SMEs providing specific technological expertise and training. The consortium will provide exceptional training to 15 ESRs, allowing them to develop professionally and perform world-class research that will fundamentally advance the field of continuous biomolecular monitoring for healthcare.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз